Ecopipam for Tourette Syndrome: A Randomized Trial
Pediatrics · 2023
DOI: 10.1542/peds.2022-059574 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pediatrics, 2023. Verfasst von Donald L Gilbert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Tourette Syndrome, Tics, Antipsychotic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES All US Food and Drug Administration-approved medications for Tourette syndrome are antipsychotics, and their use is limited by the risk of weight gain, metabolic changes, and drug-induced movement disorders. Several small trials suggest that ecopipam, a first-in-class, selective dopamine 1 receptor antagonist, reduces tics with a low risk for these adverse events. This trial sought to further evaluate the efficacy, safety, and tolerability of ecopipam in children and adolescents with moderate to severe Tourette syndrome. METHODS This was a multicenter, randomized, double-blind, placebo-controlled, phase 2b trial. Subjects aged ≥6 to <18 years with a baseline Yale Global Tic Severity Score Total Tic Score of ≥20 were randomly assigned 1:1 to ecopipam (n = 76) or placebo (n = 77). The primary endpoint was mean change over 12 weeks in the Yale Global Tic Severity Score Total Tic Score. The Clinical Global Impression of Tourette Syndrome Severity was the secondary endpoint. Safety and tolerability were evaluated at each study visit. RESULTS Total tic scores were significantly reduced from baseline to 12 weeks in the ecopipam group compared with placebo (least squares mean differences −3.44, 95% confidence interval −6.09 to −0.79, P = .01). Improvement in Clinical Global Impression of Tourette Syndrome Severity was also greater in the ecopipam group (P = .03). More weight gain was seen in subjects assigned to placebo. No metabolic or electrocardiogram changes were identified. Headache (15.8%), insomnia (14.5%), fatigue (7.9%), and somnolence (7.9%) were the most common adverse events. CONCLUSIONS Among children and adolescents with TS, ecopipam reduces tics to a greater extent than placebo, without observable evidence of common antipsychotic-associated side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
- Clintrex Research Corporation, Sarasota, Florida.
- Paragon Biosciences, LLC., Chicago, Illinois.
- ERG Clinical, Berkeley Heights, New Jersey.
- Emalex Biosciences, Inc., Chicago, Illinois.
Zitieren
APA
Gilbert, D. L., Dubow, J. S., Cunniff, T. M., Wanaski, S. P., Atkinson, S. D., & Mahableshwarkar, A. R. (2023). Ecopipam for Tourette Syndrome: A Randomized Trial. Pediatrics. https://doi.org/10.1542/peds.2022-059574
Vancouver
Gilbert DL, Dubow JS, Cunniff TM, Wanaski SP, Atkinson SD, Mahableshwarkar AR. Ecopipam for Tourette Syndrome: A Randomized Trial. Pediatrics. 2023. doi:10.1542/peds.2022-059574
BibTeX
@article{Gilbert2023,
author = {Gilbert, Donald L and Dubow, Jordan S and Cunniff, Timothy M and Wanaski, Stephen P and Atkinson, Sarah D and Mahableshwarkar, Atul R},
title = {Ecopipam for Tourette Syndrome: A Randomized Trial},
journal = {Pediatrics},
year = {2023},
doi = {10.1542/peds.2022-059574}
}
EUVIMED